ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,918.25
0.00%
US Tech 100
20,593.60
-0.08%
Dow Jones
42,635.20
0.00%
Brent Oil
79.04
2.75%
Bitcoin
95,113.44
2.92%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Compass Therapeutics Inc (CMPX) Quote

Compass Therapeutics Inc

Compass Therapeutics Inc (CMPX)

NASDAQ
1.86
0.43
(30.07%)
Closed January 08 4:00PM
Delayed by 15 minutes
2.06
0.20
( 10.75% )
Pre Market: 6:48AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
2.06
Bid
2.01
Ask
2.05
Volume
111,131
0.00 Day's Range 0.00
0.765 52 Week Range 2.68
Market Cap
283.434M
Previous Close
1.86
Open
-
Last Trade
6
@
2.05
Last Trade Time
06:48:58
Financial Volume
-
VWAP
-
Average Volume (3m)
869,425
Shares Outstanding
137,589,171
Dividend Yield
-
PE Ratio
-6.02
Earnings Per Share (EPS)
-0.31
Revenue
-
Net Profit
-42.49M

About Compass Therapeutics Inc

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engi... Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. The company has drugged over 40 immune targets and generated a diverse pipeline of monoclonal and multispecific therapeutic candidates with potential to transform care for patients with cancer or autoimmune diseases. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.compasstherapeutics.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Compass Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CMPX. The last closing price for Compass Therapeutics was $1.86. Over the last year, Compass Therapeutics shares have traded in a share price range of $ 0.765 to $ 2.68.

Compass Therapeutics currently has 137,589,171 shares outstanding. The market capitalization of Compass Therapeutics is $255.92 million. Compass Therapeutics has a price to earnings ratio (PE ratio) of -6.02.

Ask ADVFN Intelligence (AI)

CMPX Latest News

More News

Another Day, Another Biotech Stealing The Show

A biotech company based out of Boston turned heads on Wednesday after the company announced the advancement of anew drug candidate as well as provided a key update on existing To read the full...

January 08 2025
AllPennyStocks.com

Form 8-K - Current report

January 08 2025
Edgar (US Regulatory)

Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate

Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on track for end of Q1 2025.CTX-10726 (a novel PD-1 x...

January 08 2025
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

December 10 2024
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

December 10 2024
Edgar (US Regulatory)

Form 8-K - Current report

December 10 2024
Edgar (US Regulatory)

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...

December 10 2024
GlobeNewswire Inc.

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

BOSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...

December 02 2024
GlobeNewswire Inc.

Compass Therapeutics to Participate in Upcoming Investor Events

BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...

November 13 2024
GlobeNewswire Inc.

Form 8-K - Current report

November 12 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.6243.05555555561.442.681.42564614371.83990108CS
40.5132.90322580651.552.681.3317715261.78428687CS
120.157.853403141361.912.681.278694251.72251459CS
261.157128.1284606870.9032.680.87416366821.61382392CS
520.147.291666666671.922.680.7655213671.61018508CS
156-1.15-35.82554517133.215.650.7653711692.25704223CS
260-2.04-49.7560975614.15.650.7653410082.30303241CS

CMPX - Frequently Asked Questions (FAQ)

What is the current Compass Therapeutics share price?
The current share price of Compass Therapeutics is $ 2.06
How many Compass Therapeutics shares are in issue?
Compass Therapeutics has 137,589,171 shares in issue
What is the market cap of Compass Therapeutics?
The market capitalisation of Compass Therapeutics is USD 255.92M
What is the 1 year trading range for Compass Therapeutics share price?
Compass Therapeutics has traded in the range of $ 0.765 to $ 2.68 during the past year
What is the PE ratio of Compass Therapeutics?
The price to earnings ratio of Compass Therapeutics is -6.02
What is the reporting currency for Compass Therapeutics?
Compass Therapeutics reports financial results in USD
What is the latest annual profit for Compass Therapeutics?
The latest annual profit of Compass Therapeutics is USD -42.49M
What is the registered address of Compass Therapeutics?
The registered address for Compass Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Compass Therapeutics website address?
The website address for Compass Therapeutics is www.compasstherapeutics.com
Which industry sector does Compass Therapeutics operate in?
Compass Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VMARVision Marine Technologies Inc
$ 3.16
(107.89%)
18.94M
JSPRWJasper Therapeutics Inc
$ 0.3074
(98.32%)
2
IINNInspira Technologies Oxy B H N Ltd
$ 1.51
(51.00%)
8.08M
ZVSAZyVersa Therapeutics Inc
$ 1.72
(45.76%)
15.74M
BAERBridger Aerospace Group Holdings Inc
$ 4.03
(44.44%)
8.41M
IGMSIGM Biosciences Inc
$ 1.94
(-68.71%)
226.56k
XXII22nd Century Group Inc
$ 5.75
(-29.01%)
6.02k
WMPNWilliam Penn Bancorporation
$ 9.01
(-22.99%)
1
SILOSilo Pharma Inc
$ 1.33
(-22.22%)
99.69k
PCSCPerceptive Capital Solutions Corporation
$ 8.00
(-21.41%)
105
VMARVision Marine Technologies Inc
$ 3.15
(107.24%)
18.94M
ZVSAZyVersa Therapeutics Inc
$ 1.72
(45.76%)
15.74M
GCTKGlucoTrack Inc
$ 0.1259
(-9.29%)
8.75M
BAERBridger Aerospace Group Holdings Inc
$ 4.03
(44.44%)
8.41M
IINNInspira Technologies Oxy B H N Ltd
$ 1.51
(51.00%)
8.09M

CMPX Discussion

View Posts
Tiger Money Tiger Money 2 days ago
Gap filled 
👍️0
PonkenPlonken PonkenPlonken 2 days ago
and they didnt even speak about it today!
👍️0
Tiger Money Tiger Money 2 days ago
Some very good news out this morning!
👍️0
glenn1919 glenn1919 2 days ago
CMPX..................................https://stockcharts.com/h-sc/ui?s=CMPX&p=W&b=5&g=0&id=p86431144783
👍️0
Tiger Money Tiger Money 5 days ago
Thanks!
👍️0
glenn1919 glenn1919 6 days ago
sideways................higher lows.....possible breakout
👍️0
Tiger Money Tiger Money 6 days ago
What does your work tell you on this?  Thanks 
👍️0
glenn1919 glenn1919 7 days ago
cmpx.........................https://stockcharts.com/h-sc/ui?s=cmpxp=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 3 weeks ago
CMPX, under $2
👍️0
PonkenPlonken PonkenPlonken 1 month ago
Sorry for the late reply, your question got lost in the mailbox.
I believe 3-6$ isnt unreasonable if they publish a nice readout.

i believe a handful of patients showed more than 30% tumor shrinkage in vegf monotherapy data... I havent seen similar to date...... Nobody listens to webcasts anymore - they probably need an anaylst note to alert them LOL
VEGf space is full of scammers to... everyone jumped the train
👍 1
Tiger Money Tiger Money 2 months ago
If so, where do you think that puts the stock?  Thanks 
👍️0
PonkenPlonken PonkenPlonken 2 months ago
Wouldnt be surprised to see a partner announced in the 10q
👍️0
PonkenPlonken PonkenPlonken 2 months ago
boom coming never before monotherapy data in VEGF space.... a place flooded by bio grifters
👍️0
Monksdream Monksdream 3 months ago
CMPX under $2
👍️0
PonkenPlonken PonkenPlonken 3 months ago
high volume yesterday
👍️0
PonkenPlonken PonkenPlonken 4 months ago
EXCELLENT monotherapy data
VEGF targeted agents usually need the chemo combination to even get a signifcant response. They get it in monotherapy.
I think its going to run into the H1 2025 data.
👍️0
Monksdream Monksdream 4 months ago
CMPX under $2
👍️0
glenn1919 glenn1919 4 months ago
CMPX........................................https://stockcharts.com/h-sc/ui?s=CMPX&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 5 months ago
CMPX....................https://stockcharts.com/h-sc/ui?s=CMPX&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 5 months ago
CMPX under $2
👍️0
Monksdream Monksdream 10 months ago
CMPX 10Q due 3/25
👍️0
Monksdream Monksdream 10 months ago
CMPX 10Q due 3/18
👍️0
glenn1919 glenn1919 10 months ago
CMPX....................................https://stockcharts.com/h-sc/ui?s=CMPX&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 10 months ago
Cant say offhand
Read the latest 10Q
👍️0
stockweiser stockweiser 10 months ago
Do you know there current cash on hand?
👍️0
Monksdream Monksdream 10 months ago
CMPX 10Q due March 11
👍️0
Monksdream Monksdream 12 months ago
CMPX new 52=week low
👍️0
Monksdream Monksdream 1 year ago
CMPX new 52 week low
👍️0
Monksdream Monksdream 1 year ago
CMPX under $2
👍️0
Copilotdog Copilotdog 1 year ago
Solid company
👍️0
Mktman2024 Mktman2024 2 years ago
Compass to review latest phase 2 progress with CTX 009 and other items at ASCO Jan 19-21.
Company moving slowly into the spotlight.
👍️0
Mktman2024 Mktman2024 2 years ago
Reminder CMPX is Compass Therapeutics ,,,EF Hutton new target 10
targets range from 8-15
👍️0
Mktman2024 Mktman2024 2 years ago
https://www.streetinsider.com/Corporate+News/Compass+Therapeutics%2C+Inc+%28CMPX%29+doses+first+patient+in+Phase+1b+CTX-471+combo+with+KEYTRUDA/20920046.html

now were talking!!
👍️0
Mktman2024 Mktman2024 2 years ago
amazing no one posts on any CMPX boards except twitter ...and even then crickets
👍️0
Mktman2024 Mktman2024 2 years ago
The proper company name associated with CMPX symbol
Compass Therapeutics . If one were to review the 6 or 7 bispecifics currently approved for cancer, the efficacy of CTX 009 , CTX 471 and CTX 8371 in early trials is astounding...with a very unique Moa...still not understood by most analysts. It clearly warrants a collaboration with Merck on 471 and potentially many others. The stitchmab they have developed is a real game changing technology optimizing the best suitable mab combinations , along with Taxol, Keytruda and others ...supercharging the efficacy of current drug therapies. This stock has multiple undervalued assets.
👍️0
Mktman2024 Mktman2024 2 years ago
Do you think they like their company ...a little??

Compass Therapeutics, Inc. Insider Trading Activity (benzinga.com)
👍️0
NO birds Allowed NO birds Allowed 2 years ago
dude WTF!!!! another ALLM
👍️0
NO birds Allowed NO birds Allowed 2 years ago
is eh CEO still buying?
👍️0
Mktman2024 Mktman2024 2 years ago
The relative outperformance continues stock sits at 3.05 .Phase 2/3 in US will begin Q4 ...more oustanding data to follow. 3X is easy with this one.
👍️0
Mktman2024 Mktman2024 2 years ago
CEO continues to buy stock buys another 15000 filed 8/17 owns over 5.3 million shares

https://ih.advfn.com/stock-market/NASDAQ/compass-therapeutics-CMPX/stock-news/88862025/statement-of-changes-in-beneficial-ownership-4
👍️0
Mktman2024 Mktman2024 2 years ago
Now we're talking !! 3.00 then 3.27 news might be coming fairly soon
New data plus CTX 009 US trial enrollment . winner..
👍️0
Mktman2024 Mktman2024 3 years ago
Could the rocket be on the launching pad ?? volume building nicely for a name thats still under the radar.
👍️0
Mktman2024 Mktman2024 3 years ago
Awaiting further data on CTX 009 and the expansion of trials to the US
👍️0
NO birds Allowed NO birds Allowed 3 years ago
I forgot to ask, have you or brooklyn participated in this last raise?I am waiting for the next one at .05
👍️0
NO birds Allowed NO birds Allowed 3 years ago
you must have guessed by now that we have a mutual friend involved in both of these stocks
👍️0
NO birds Allowed NO birds Allowed 3 years ago
hello old friend, this looks so much better than the other
👍️0
Mktman2024 Mktman2024 3 years ago
To present at Jefferies H/C conf. june 9th...will they join the recommended list there too?
👍️0
Mktman2024 Mktman2024 3 years ago
CEO buys 60,000 more on 5/28 owns 5.2 +million
👍️0
Mktman2024 Mktman2024 3 years ago
Still amazed no posts on any stock msg boards Its under the retail radar so far while its 67% institutionally owned 5 analysts cover targets 9 11 15 to name a few.....add to this recent institutional buying as well as insider buys...Founders came from Orbimed. I'm all in.
👍️0
Mktman2024 Mktman2024 3 years ago
B of A health conf went great . more exposure to this company with some amazing drug discovery anti tumor tech. Waiting to see more coverage upgrades and target price increases .Major board members buying more at 2.50...company still well under the radar .My number one pick for 2022-2023. potential 5 to 10 X from here. Targets still way too low.
👍️0

Your Recent History

NASDAQ
CMPX
Compass Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads